Clinical Utility of the 70-gene MammaPrint Profile in a Japanese Population

Publication Name: Japanese Journal of Clinical Oncology

Author(s): Makoto Ishitobi, Teodora Goranova, Yoshifumi Komoike, Kazuyoshi Motomura, Hiroki Koyama, Annuska Glas, Ellen van Lienen, Hideo Inaji Laura van’t Veer and Kikuya Kato

Objective: van’t Veer and colleagues developed a 70-gene prognosis profile known as MammaPrint to identify breast cancer patients who were at low risk of developing metastases. We evaluated the prognostic value of the 70-gene MammaPrint profile in Japanese women with … Continued

Use of a genomic test (MammaPrint) in daily clinical practice to assist in risk stratification of young breast cancer patients

Publication Name: Archives of Gynecology and Obstetrics

Author(s): Georg Kunz

Purpose: Breast cancer as a heterogeneous disease demands reliable tools in order to identify those patients who most likely will benefit from receiving adjuvant treatment, such as chemotherapy. MATERIALS AND METHODS: The MammaPrint test was established on the basis of … Continued

MammaPrint 70-gene profile quantifies the likelihood of recurrence for early breast cancer.

Publication Name: Expert Opinion Medical Diagnostics

Author(s): Phillipe L Bedard, Stella Mook, Martine J Piccart-Gebhart, Emiel T Rutgers, Laura J van ‘t Veer and Fatima Cardoso

Background: Over the past few years, a variety of multigene expression profiles have been developed to improve prognostication for early stage breast cancer and reduce overtreatment with chemotherapy. MammaPrint is the only test cleared by the US Food and Drug … Continued

Microarray-Based Determination of Estrogen Receptor, Progesterone Receptor, and HER2 Receptor Status in Breast Cancer

Publication Name: Clinical Cancer Research

Author(s): Paul Roepman, Hugo M. Horlings, Oscar Krijgsman, Marleen Kok, Jolien M. Bueno-de-Mesquita, Richard Bender, Sabine C. Linn, Annuska M. Glas and Marc J. van de Vijver

Purpose: The level of estrogen receptor (ER), progesterone receptor (PR), and HER2 aids in the determination of prognosis and treatment of breast cancer. Immunohistochemistry is currently the predominant method for assessment, but differences in methods and interpretation can substantially affect … Continued

The 70-gene prognosis signature predicts early metastasis in breast cancer patients between 55 and 70 years of age.

Publication Name: Annals of Oncology

Author(s): Mook S, Schmidt MK, Weigelt B

Background: The majority of breast cancer patients are postmenopausal women who are increasingly being offered adjuvant chemotherapy. Since the beneficial effect of chemotherapy in postmenopausal patients predominantly occurs in the first 5 years after diagnosis, a prognostic marker for early … Continued

Validation of 70-gene prognosis signature in node-negative breast cancer

Publication Name: Breast Cancer Research & Treatment

Author(s): Bueno-de-Mesquita JM, Keijzer R, Linn SC

Purpose: The 70-gene prognosis signature (van’t Veer et al., Nature 415(6871):530–536, 2002) may improve the selection of lymph node-negative breast cancer patients for adjuvant systemic therapy. Optimal validation of prognostic classifiers is of great importance and we therefore wished to … Continued

The 70-gene prognosis-profile predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study

Publication Name: Breast Cancer Research and Treatment

Author(s): Mook, S, Schmidt, M.S., Viale, G

Purpose: The 70-gene prognosis-signature has shown to be a valid prognostic tool in node-negative breast cancer. Although axillary lymph node status is considered to be one of the most important prognostic factors, still 25–30% of node-positive breast cancer patients will … Continued

Use of a 70-Gene Signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER).

Publication Name: Lancet Oncology

Author(s): Jolien M Bueno-de-Mesquita MD, Prof Wim H van Harten MD, Valesca P Retel MSc, Laura J van 't Veer PhD, Prof Frits SAM van Dam PhD, Kim Karsenberg MSc, Kirsten FL Douma MSc, Harm van Tinteren PhD, Johannes L Peterse MD, Jelle Wesseling MD, Tin S Wu MSc, Douwe Atsma BSc, Prof Emiel JT Rutgers MD, Guido Brink BSc, Arno N Floore BSc, Annuska M Glas PhD, Rudi MH Roumen MD, Frank E Bellot MD, Cees van Krimpen MD, Prof Sjoerd Rodenhuis MD, Prof Marc J van de Vijver MD, Dr Sabine C Linn MD

Background: A microarray-based 70-gene prognosis signature [MammaPrint] might improve the selection of patients with node-negative breast cancer for adjuvant systemic treatment. The main aims of this MicroarRAy PrognoSTics in Breast CancER (RASTER) study were to assess prospectively the feasibility of … Continued

Validation and Clinical Utility of a 70-Gene Prognostic Signature for Women With Node-Negative Breast Cancer

Publication Name: Journal of the National Cancer Institute

Author(s): Marc Buyse, Sherene Loi, Laura van’t Veer, Giuseppe Viale, Mauro Delorenzi, Annuska M. Glas, Mahasti Saghatchian d’Assignies, Jonas Bergh, Rosette Lidereau, Paul Ellis, Adrian Harris, Jan Bogaerts, Patrick Therasse, Arno Floore, Mohamed Amakrane, Fanny Piette, Emiel Rutgers, Christos Sotiriou, Fatima Cardoso, Martine J. Piccart

Background: A 70-gene signature was previously shown to have prognostic value in patients with node-negative breast cancer. Our goal was to validate the signature in an independent group of patients. Methods: Patients (n = 307, with 137 events after a … Continued

A Gene-Expression Signature as a Predictor of Survival in Breast Cancer.

Publication Name: New England Journal of Medicine

Author(s): Marc J. van de Vijver, M.D., Ph.D., Yudong D. He, Ph.D., Laura J. van 't Veer, Ph.D., Hongyue Dai, Ph.D., Augustinus A.M. Hart, M.Sc., Dorien W. Voskuil, Ph.D., George J. Schreiber, M.Sc., Johannes L. Peterse, M.D., Chris Roberts, Ph.D., Matthew J. Marton, Ph.D., Mark Parrish, Douwe Atsma, Anke Witteveen, Annuska Glas, Ph.D., Leonie Delahaye, Tony van der Velde, Harry Bartelink, M.D., Ph.D., Sjoerd Rodenhuis, M.D., Ph.D., Emiel T. Rutgers, M.D., Ph.D., Stephen H. Friend, M.D., Ph.D., and René Bernards, Ph.D.

Background: A more accurate means of prognostication in breast cancer will improve the selection of patients for adjuvant systemic therapy. Methods: Using microarray analysis to evaluate our previously established 70-gene prognosis profile, we classified a series of 295 consecutive patients … Continued